Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone as adjunctive therapy in MDD
NCT05061706Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of lumateperone in major depressive disorder (MDD), sponsored by Intra-Cellular Therapies. Started Sep 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05061706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061706.